Mitochondrial DNA copy number is reduced in male combat veterans with PTSD

Permalink
https://escholarship.org/uc/item/1k0456d5

Journal
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 64

ISSN
0278-5846

Authors
Bersani, FS
Morley, C
Lindqvist, D
et al.

Publication Date
2016-01-04

DOI
10.1016/j.pnpbp.2015.06.012

Peer reviewed
Mitochondrial DNA copy number is reduced in male combat veterans with PTSD

Francesco Saverio Bersani a,b, Claire Morley a, Daniel Lindqvist a,c, Elissa S. Epel a,d, Martin Picard e, Rachel Yehuda f, Janine Flory f, Linda M. Bierer f, Iouri Makotkine f, Duna Abu-Amara g, Michelle Coy a, Victor I. Reus a, Jue Lin h, Elizabeth H. Blackburn h, Charles Marmar e, Owen M. Wolkowitz n,e, Synthia H. Mellon i

Abstract

Introduction: Mitochondrial abnormalities may be involved in PTSD, although few studies have examined this. Mitochondrial DNA copy number (mtDNAcn) in blood cells is an emerging systemic index of mitochondrial bio-genesis and function. The present study assessed mtDNAcn in male combat-exposed veterans with PTSD compared to those without PTSD as well as its correlation with clinical scales.

Methods: mtDNAcn was assessed with a TaqMan multiplex assay in granulocytes of 43 male combat veterans with (n = 43) or without (n = 44) PTSD. Twenty of the PTSD subjects had co-morbid major depressive disorder (MDD). The Clinician Administered PTSD Scale (CAPS), the Positive and Negative Affect Schedule (PANAS), the Early Trauma Inventory (ETI) and the Beck Depression Inventory II (BDI-II) were used for the clinical assessments. All analyses were corrected for age and BMI.

Results: mtDNAcn was significantly lower in subjects with PTSD (p < 0.05). Within the PTSD group, those with moderate PTSD symptom severity had relatively higher mtDNAcn than those with mild or severe symptoms (p < 0.01). Within the PTSD group, mtDNAcn was positively correlated with PANAS positive subscale ratings (p < 0.01) but was not significantly correlated with PANAS negative subscale, ETI or BDI-II ratings.

Discussion: This study provides the first evidence of: (i) a significant decrease of mtDNAcn in combat PTSD, (ii) a possible “inverted-U” shaped relationship between PTSD symptom severity and mtDNAcn within PTSD subjects, and (iii) a direct correlation of mtDNAcn with positive affectivity within PTSD subjects. Altered mtDNAcn in PTSD may reflect impaired energy metabolism, which might represent a novel aspect of its pathophysiology.

1. Introduction

Post-traumatic stress disorder (PTSD) is a debilitating mental illness characterized by recurrent distressing memories of an initial traumatic event, emotional numbing and hyperarousal (APA, 2013). In addition to the traditional psychiatric symptoms, individuals with PTSD have a substantially higher medical burden, with increased rates of cardiometabolic disturbances and early mortality, suggesting widespread physical and biological concomitants of the disease (Levine et al., 2014). Such physical and biological concomitants of PTSD may, in part, result from significant dysfunctions in several cellular processes including
alterations in inflammation (Lindqvist et al., 2014; Wilson et al., 2013), oxidative stress (Cseprija et al., 2011; Wilson et al., 2013), telomere homeostasis (Jergovic et al., 2014; O’Donovan et al., 2011), neuroendocrine regulation (Rasmusson et al., 2010; Yehuda, 2001), nitric oxide (NO) production (Bersani et al., 2015; Lopez-Figueroa et al., 1998; Yeh et al., 2002) and mitochondrial activity (Li et al., 2014; Mellon et al., 2015; Su et al., 2008).

Mitochondria are ubiquitous organelles of eukaryotic systems (Johannsen and Ravussin, 2009; Scheffler, 2001). They can be considered the “power generators” of the cell, converting oxygen, energy substrates (carbohydrates and lipids) and other compounds via oxidative phosphorylation into adenosine triphosphate (ATP), which is then transported to the cell’s cytoplasm to fuel the majority of cellular reactions (Johannsen and Ravussin, 2009; Scheffler, 2001). Beyond energy production, mitochondria also play key roles in other crucial cellular processes such as apoptotic and necrotic cell death (Johannsen and Ravussin, 2009; Kasahara and Scorrano, 2014), regulation of gene expression (Johannsen and Ravussin, 2009; Kasahara and Scorrano, 2014; Picard et al., 2014b), and signal transduction for cell proliferation and differentiation (Johannsen and Ravussin, 2009; Kasahara and Scorrano, 2014). As a result, mitochondrial impairments are associated with, and may lead to, widespread psychiatric and somatic illnesses, with brain, heart and metabolism being especially vulnerable (Dimauro and Davidzon, 2005; Marazziti et al., 2012).

Cells of different tissues contain multiple mitochondria, and, in turn, each mitochondrion contains multiple copies of its own genome – the mitochondrial DNA (mtDNA) – which encodes 37 genes essential to energy production (Campbell et al., 2012; Clay Montier et al., 2009). One way of indirectly assessing mitochondrial function is by measuring the number of mtDNA molecules per cell, namely mitochondrial DNA copy number (mtDNAcn). MtDNAcn is also matched to cellular energy needs. High-energy requiring cells, such as heart, skeletal muscles and neurons require large quantities of ATP and maintain high numbers of mtDNA copies while low-energy requiring cells, such as spleen and endothelial cells, maintain fewer copies (Moyes et al., 1998). Certain brain regions also contain varying amounts of mitochondria (Fuke et al., 2011). In addition to baseline differences, changes in mtDNA can reflect variations in mitochondrial biogenesis (i.e. the formation of new mitochondria). Exercise increases cellular energy demand and, as a compensatory response, enhances energy production capacity through mitochondrial biogenesis, which can be detected as an increased mtDNAcn in various brain regions and other tissues (Steiner et al., 2011). On the other hand, mitochondrial content in skeletal muscle tends to decrease in sedentary individuals with aging, and this is reflected by a lower mtDNAcn (Short et al., 2005). MtDNAcn is therefore considered a marker of mitochondrial energetic function (Clay Montier et al., 2009; Moyes et al., 1998) and biogenesis (Clay Montier et al., 2009; Lee and Wei, 2005).

While the exact meaning/significance of mtDNAcn is still not completely known, the importance of mtDNAcn maintenance for cell physiology and homeostasis is underscored by the evidence of altered mtDNAcn associated with diverse types of human disease, including developmental delays in early childhood (Macmillan and Shoubridge, 1996), multiple sclerosis (Blokland et al., 2008), renal and breast cancers (Xing et al., 2008; Yu et al., 2007), liver disease (Morten et al., 2007), biliary atresia (Tiao et al., 2007), type 2 diabetes (Choi et al., 2001; Lee et al., 1998), insulin resistance (Choi et al., 2001; Lee et al., 1998), cardiomyopathy (Bai and Wong, 2005) and metabolic syndrome (Kim et al., 2001; Lee and Wei, 2005). Also, certain genetic defects that impair mitochondrial biogenesis can lead to depletion of mtDNA, which dramatically reduces mitochondrial energy production capacity leading to multisystemic disease (Al-Hussaini et al., 2014; Hudson and Chinmery, 2006). However, excessive levels of mtDNAcn can also be, less commonly, associated with disease (Clay Montier et al., 2009). This highlights the importance of appropriate regulation of a “just right” level of mtDNAcn for adaptive cellular physiology (Clay Montier et al., 2009).

A small number of studies also examined mtDNAcn (primarily in leukocytes) in relation to psychiatric disturbances, showing conflicting results. The mtDNAcn has been reported to be significantly high in autism (Giulivi et al., 2010), significantly reduced in some (but not in all) studies on bipolar disorder (Chang et al., 2014; de Sousa et al., 2014; Kakiuchi et al., 2005; Sabunciyian et al., 2007; Torrell et al., 2013; Vawter et al., 2006) and positively associated with childhood adversity and lifetime psychopathology in healthy people (Tyrka et al, in press). A recent study in community-dwelling women (n = 142) found significantly lower mtDNAcn in people with higher depressive symptoms (not necessarily diagnosed with Major Depressive Disorder [MDD]) compared to those with lower depressive symptoms (Kim et al., 2011). However, one study found that mtDNAcn was not significantly different in subjects with MDD compared to controls (He et al., 2014).

Although mtDNAcn has never previously been examined in PTSD, a small number of studies has examined mitochondrial function in this condition. In a post-mortem study, Su et al. investigated gene expression profiles in the dorsolateral-prefrontal cortex (DLPFC) of subjects with PTSD vs controls (Su et al., 2008). They found that, of the 119 dysregulated genes in PTSD subjects, large clusters of functionally-related genes were associated with mitochondrial dysfunction (4.8%) and oxidative phosphorylation (3.8%) (Su et al., 2008). Li et al. found altered expression of mitochondrial genes in the amygdala of an animal model of PTSD (Li et al., 2014). A metabolomic study from our research team found PTSD subjects to have significantly altered plasma concentrations of several metabolites, consistent with mitochondrial dysfunction (i.e. altered Krebs cycle metabolites, carnitines and ketone bodies) (Mellon et al., 2015).

There is a need to study mitochondria in an accessible way in well-characterized PTSD samples, so that we may better understand how mitochondrial abnormalities may be related to the pathophysiology of the disease. In this research, we assessed granulocyte mtDNAcn in a sample of male war veterans with PTSD in comparison with psychiatrically healthy male war veterans without PTSD (i.e. controls). We hypothesized that mtDNAcn would be decreased in PTSD and would be inversely associated with the severity of clinical ratings.

2. Methods

2.1. Ethical statement

The Institutional Review Boards of Icahn School of Medicine at Mount Sinai (ISMM; New York, NY), the James J. Peters Veterans Administration Medical Center (JJPVAMC; Bronx, New York), New York University Medical Center (NYU; New York, NY), and the University of California, San Francisco, Medical Center (UCSF; San Francisco, CA) approved this study. Study participants gave written and informed consent to participate. The study was conducted in accordance with the provisions of the Helsinki Declaration.

2.2. Recruitment procedures and study participants

Eighty-seven Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF) male combat-exposed veterans participated. Forty-three of the participants were diagnosed with current PTSD, while 44 did not have PTSD (i.e. controls). Among the PTSD subjects, 20 were diagnosed with concurrent MDD. Participants were recruited by NYU, ISMMs and JJPVAMC. Subjects were recruited from the Mental Health Services of the Manhattan, Bronx and Brooklyn Veterans Affairs Medical Centers, other regional VA medical centers, Veterans Service Organizations, National Guard, reservist agencies and organizations and from the general community. Recruitment methods included flyers, in-person presentations, media advertisements, internet postings (e.g. Craigslist) and referral from clinicians. Participants were compensated for their participation. Criteria for inclusion were: (a) PTSD subjects were positive for the presence of current combat-related PTSD of at
least 3 months duration, as defined by the DSM-IV (First, 1997), and the Clinician Administered PTSD Scale (CAPS) (Blake et al., 1990) criteria with a current CAPS score > 40 (one PTSD subject met DSM-IV criteria for PTSD but was missing CAPS data; he was included in the study); (b) control subjects were also combat-exposed but were negative for lifetime PTSD and had a current CAPS score < 20; (c) age between 20 and 60; (d) males; and (e) proficient in the English language. The following exclusion criteria were employed for all subjects: (a) history of alcohol dependence within the past 8 months; (b) history of drug abuse or dependence (except nicotine dependence) within the past year; (c) lifetime history of any psychiatric disorder with psychotic features, bipolar disorder, or obsessive-compulsive disorder; (d) those who were currently exposed to recurrent trauma or have been exposed to a traumatic event within the past 3 months; (e) subjects with prominent suicidal or homicidal ideation; (f) neurologic disorder or systemic illness affecting central nervous system function; (g) history of anemia, recent blood donation in the past 2 months; (i) subjects on medication who were not stable for 2 + months on psychiatric medication, anticonvulsants, antihypertensive medication or sympathomimetic medication; (j) subjects who were classified with a moderate or severe traumatic brain injury (TBI) on the Ohio State University TBI Identification Method—Short Form; and finally (k) subjects who experienced loss of consciousness for greater than 10 min. All study participants experienced combat traumas described in criterion A of DSM-IV PTSD diagnostic criteria. Structured Clinical Interviews for DSM-IV disorders (SCID) (First, 1997) were conducted by doctoral level psychologists, and were audio recorded and calibrated weekly with a senior clinician in the PTSD program.

2.3. Psychiatric and psychological assessment measures

The SCID was used to determine whether participants met DSM-IV diagnostic criteria for any psychiatric disorder (First, 1997). The CAPS was used to determine the severity of current PTSD symptoms (past month; “CAPS current”) and the severity of the most severe lifetime episode of combat-related PTSD (“CAPS lifetime”) (Blake et al., 1990). The Positive and Negative Affect Schedule (PANAS) was used to assess the positive and negative affectivity (Watson et al., 1988). Depression symptom severity was assessed with the self-rated Beck Depression Inventory-II (BDI-II) (Beck et al., 1996). Exposure to early life trauma was evaluated using the Early Trauma Inventory (ETI)—Self Report Short Form (Bremner et al., 2007).

2.4. Blood samples and measurement of mtDNA copy number

Blood was drawn in the morning after a night of fasting. Whole blood was collected into 10 ml EDTA Lavender Top (LLT) tubes and granulocytes were isolated and stored at −80°C. Peripheral blood mononuclear cells (PBMCs) were purified whole blood using standard Ficoll gradient centrifugation method. Granulocytes were prepared from the red blood pellets after Ficoll separation of the PBMCs by lysing in three volumes of ACK lysis buffer (Qiagen, cat # 158902). The cells were left in ACK lysis buffer at room temperature for 10 min with inversion every 2 min. The cells were spun at 400 g for 10 min in a Sorvall Legend RT tabletop centrifuge at 10°C. The cell pellets were washed twice with 10 ml of cold DPBS (Invitrogen, cat # 14040-133) and spun at 400 g for 10 min at 10°C. After the second wash, the cell pellets were resuspended in 5 ml of DPBS, aliquoted into 5 of 1.5 ml Eppendorf tubes, spun at 7000 rpm for 5 min at 4°C, and were stored at −80°C for batch DNA purification. DNA was purified using QiAamp blood mini kit (cat#: 51106) based on the manufacturer’s manual and quantity were assessed with a nanodrop spectrophotometer. Relative copy number of mtDNA per diploid nuclear genome was determined using a TaqMan multiplex assay by the detection of a 69 bp fragment of the ND1 gene in mtDNA (nucleotides 3485–3553) and an 87 bp fragment of RNase P (TaqMan® Copy Number Reference Assay, Iuman, RNase P, cat# 4403328, Life Technologies) in the nuclear genomic DNA (nDNA). This assay was adapted from previous published methods (He et al., 2002). The primer and probe sequences for ND1 are: ND1-forward [5′-CCCTAAAAACCCGCC ACATCT-3′], ND1-reverse [5′-GACCGATGGTGACGACTAAGGT-3′], ND1- FAM probe [5′-FAM-CCATCACCCTACTACGCCCT-TAMRA-3′]. The reaction contained 12.5 ng of total cellular (nuclear plus mitochondrial) genomic DNA, 100 nM of ND1 probe, 300 nM each of ND1-forward primer and ND1-reverse primer each, 1 × RNase P copy number Reference Assay, 1 × LightCycler® 480 Probe Master (Roche, cat# 04902343001) in a 10 µl reaction. All samples were run in triplicate wells in 384-well plates in a Roche LightCycler 480. PCR condition is 95°C 10 min for 1 cycle; 45 cycles of 95°C 10 s, 60°C 30 s, 72°C 1 s with data acquisition at 72°C. Crossing point (Cp) for each well is derived by the LightCycler 480 program using the second derivation method. Relative copy number per diploid genome (i.e. per cell) is calculated by the following formula: Relative mtDNAcn = POWER(2, (CpND1 − CpRNaseP)) × 2. Inter-assay CV is 3.4% and intra-assay CV is 0.5%.

2.5. Statistical analysis

The Statistical Package for the Social Sciences (SPSS) was used for statistical calculations. All tests were 2-tailed with an alpha = 0.05. Significance values between 0.05 and 0.10 are reported as trends. Data are expressed as means ± SD. The mtDNAcn across groups was not normally distributed and thus was transformed into normality using the Blom transformation, a statistical procedure replacing each raw score with its rank value and adjusting the scale distances between the ranks to achieve a normal distribution (Blom, 1958); all other data were normally distributed. The Mann–Whitney U-test for continuous variables or the chi-square test for dichotomous variables was used to examine participants’ baseline between-group differences. One-way analysis of covariance (ANCOVA) adjusting for age and body mass index (BMI), for their known association with mtDNA (Bratic and Larsson, 2013; Lee et al., 2014), was used to test for mtDNA intergroup differences. ANCOVA’s were also performed to determine whether PTSD subjects with or without comorbid MDD, or with or without current antidepressant use, had significantly different mtDNAcn. Within PTSD subjects, Pearson partial correlation and quadratic regression using the same covariates (i.e age and BMI) were used to determine associations between mtDNAcn and the clinical assessment scales.

3. Results

3.1. Demographics and clinical characteristics of the sample

Demographic and clinical characteristics of the subjects are presented in Table 1. There were no significant differences with regard to age, years of education and smoking status. Hispanic ethnicity was more frequently represented in the PTSD sample. In addition, the amount of time since the index combat event was significantly longer in PTSD subjects. The use of antidepressant drugs was more common in the PTSD group (p < 0.001), likely due to the PTSD group having cases of comorbid MDD and due to the use of antidepressants as a treatment for PTSD (Albucher and Liberzon, 2002). However, the PTSD and control groups did not significantly differ in their use of other medications (e.g., statins, non-steroidal anti-inflammatory drugs (NSAIDs), anti-diabetic drugs). Subjects with comorbid somatic disorders (clinical hypotension, stable angina, prostate cancer and diabetes) were equally distributed across groups. As expected, subjects with PTSD compared to controls had significantly or near significantly higher scores on BDI-II (p < 0.001), PANAS negative subscale (p < 0.001), ETI (p = 0.084), CAPS current (p < 0.001) and CAPS lifetime (p < 0.001) symptom severity scales, and significantly lower scores on PANAS positive subscale (p < 0.001).
3.2. Intergroup differences in mtDNA copy number

The mean mtDNAcn per cell in the PTSD group was 186.027 ± 63.875, compared to 207.785 ± 72.329 in the control group (Fig. 1). One-way ANCOVA (covarying for age and BMI) determined significant differences in mean mtDNAcn (F(1, 82) = 4.239, p = 0.043) between the two groups. The mtDNAcn did not significantly differ between PTSD subjects with (183.143 ± 67.289) or without (188.536 ± 62.126) comorbid MDD (p = 0.746), or between PTSD subjects who did (190.539 ± 80.244) or did not (184.891 ± 56.288) use antidepressants (p = 0.128).

3.3. Association of mtDNA copy number with clinical measures within PTSD sample

To explore the relationship between PTSD symptom severity and mtDNAcn within the PTSD group, PTSD subjects were divided in tertiles according to ratings on the CAPS current scale. The mtDNAcn was 159.402 ± 51.668 for the “mild PTSD” subgroup (n = 14; CAPS current score range: 44–56), 231.239 ± 81.528 for the “moderate PTSD” subgroup (n = 14; CAPS current score range: 57–75) and 168.586 ± 23.515 for the “severe PTSD” subgroup (n = 14; CAPS current score range: 76–100) (Fig. 2). Age, BMI, number of individuals with concomitant MDD diagnosis and number of individuals using antidepressants were not significantly different between the three sub-groups (p > 0.15). One-way ANCOVA (covarying for age and BMI) determined significant differences in mean mtDNAcn (F(2, 37) = 6.479, p = 0.004) between the three subgroups. Post-hoc Bonferroni testing revealed that subjects with moderate PTSD had significantly higher mtDNAcn than subjects with either mild (p = 0.006) or severe (p = 0.018) PTSD, but did not differ significantly from controls (p = 1.000).

---

**Table 1**

Demographic and clinical characteristics of PTSD subjects and controls.

<table>
<thead>
<tr>
<th></th>
<th>PTSD</th>
<th>Controls</th>
<th>Mann–Whitney U-test</th>
<th>chi²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years, mean ± SD)</td>
<td>34.49 ± 8.15</td>
<td>32.16 ± 8.55</td>
<td>0.075</td>
<td></td>
</tr>
<tr>
<td>Years of education (mean ± SD)</td>
<td>12.86 ± 3.90</td>
<td>13.20 ± 5.39</td>
<td>0.107</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td>All males</td>
<td>All males</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smokers (n)</td>
<td>7</td>
<td>3</td>
<td></td>
<td>0.161</td>
</tr>
<tr>
<td>BMI (mean ± SD)</td>
<td>30.34 ± 5.55</td>
<td>28.08 ± 4.25</td>
<td>0.070</td>
<td></td>
</tr>
<tr>
<td>Hispanic/non-Hispanic (n)</td>
<td>23/19</td>
<td>15/29</td>
<td></td>
<td>0.054*</td>
</tr>
<tr>
<td>Time since index combat event (months, mean ± SD)</td>
<td>68.68 ± 25.75</td>
<td>51.89 ± 24.99</td>
<td>0.003*</td>
<td></td>
</tr>
</tbody>
</table>

**Medications**

- Taking statins (n) 2 1 0.572
- Taking antidepressants (n) 14 1 <0.001*
- Taking NSAIDs (n) 3 2 0.625
- Taking antidiabetic drugs (n) 1 0 0.321

**Comorbid diseases**

- Clinical hypertension (n) 5 4 0.794
- Stable angina (n) 2 1 0.463
- Diabetes (n) 3 0 0.122
- Prostate cancer (n) 0 1 0.320

**Clinical measures**

- CAPS total current (mean ± SD) 68.52 ± 16.34 3.77 ± 5.47 <0.001*
- CAPS total lifetime (mean ± SD) 93.45 ± 13.55 9.09 ± 8.57 <0.001*
- BDI-II (mean ± SD) 23.50 ± 10.39 5.72 ± 6.77 <0.001*
- ETI (mean ± SD) 8.19 ± 5.85 5.91 ± 4.35 0.084
- PANAS positive (mean ± SD) 25.31 ± 7.29 33.84 ± 9.59 <0.001*
- PANAS negative (mean ± SD) 28.57 ± 8.60 15.23 ± 5.30 <0.001*
- MDD diagnosis (n) 20 0

* p ≤ 0.05.
The relationship between CAPS current ratings and mtDNAcn did not fit a linear correlation ($r = -0.027, p = 0.869$) but, rather, approximated a curvilinear quadratic correlation ($r = 0.363, p = 0.064$). On the other hand, mtDNAcn was significantly positively correlated with PANAS positive affect subscale in a linear manner ($r = 0.437, p = 0.005$) (Fig. 3) but not with PANAS negative affect subscale ($r = 0.218; p = 0.177$), ETI ($r = -0.030; p = 0.856$), CAPS lifetime ($r = 0.052; p = 0.750$) or BDI-II ($r = 0.053; p = 0.744$). Lastly, mtDNAcn was not significantly correlated with time since the index combat event within the PTSD group ($r = 0.228, p = 0.163$).

4. Discussion

This is the first study assessing the mtDNAcn, a widely used marker of mitochondrial function and biogenesis (Clay Montier et al., 2009), in individuals with PTSD and its correlation with clinical measures. Our results showed (i) a significantly lower granulocyte mtDNAcn in combat-exposed male PTSD subjects compared to combat-exposed male controls without PTSD (Fig. 1), (ii) an inverted-U-shaped relationship between mtDNAcn and PTSD severity (i.e., subjects with moderate current PTSD had relatively higher mtDNAcn that subjects with either mild or severe current PTSD) (Fig. 2), and (iii) a significant direct correlation between mtDNAcn and positive affectivity within PTSD subjects (Fig. 3). The mean mtDNAcn was not different between PTSD subjects with or without co-morbid MDD as well as between PTSD subjects taking or not taking antidepressants, suggesting that the observed decrease in mtDNAcn in PTSD is likely not attributable to comorbid MDD diagnosis or antidepressant use.

Even though some previous clinical studies have shown alterations in mtDNAcn in various psychiatric disorders including autism, MDD and bipolar disorder (Chang et al., 2014; Giulivi et al., 2010; Kim et al., 2011), this is the first study to investigate mtDNAcn in PTSD. A small number of clinical or pre-clinical studies (reviewed in the Introduction) previously implicated mitochondrial dysfunction in the pathophysiology of PTSD (Li et al., 2014; Mellon et al., 2015; Su et al., 2008). However, our study differs from those by studying a clinical sample rather than an animal model and by using in vivo blood-based, rather than post-mortem brain-based, mitochondrial markers.

Several mechanisms might help explain the decreased mtDNAcn in PTSD. At the cellular level, mtDNAcn is tightly regulated (Bai et al., 2000; Cao et al., 2007; Clay Montier et al., 2009), with (i) low (“sub-threshold”) mtDNAcn generally triggering an up-regulation of mtDNA replication and high (“supra-threshold”) mtDNAcn generally triggering mtDNA degradation (Clay Montier et al., 2009), and (ii) specific mtDNA regulatory proteins contributing to the maintenance of mtDNAcn within a physiologic range (Campbell et al., 2012; Clay Montier et al., 2009). Our data showing lower mtDNAcn in individuals with PTSD raise the possibility that PTSD is characterized by dysregulated mtDNAcn thresholds and/or maintenance, with significantly increased degradation or decreased replication of mtDNA in comparison to controls. Our finding of decreased mtDNAcn in PTSD is also consistent with the findings of Su et al. (Su et al., 2008) and Li et al. (Li et al., 2014) showing that a high number of genes related to mitochondrial function may be dysregulated in PTSD or animal models of PTSD, although the specific cellular effects of these dysregulations are not completely known.

At the neurobiological level, PTSD has been associated with down-regulation of glucocorticoid and serotonergic systems, as well as with reduced NO production, although conflicting results exist (Bersani et al., 2015; Bugajski, 1999; Harris et al., 2000; Lopez-Figueroa et al., 1998; Meewisse et al., 2007; Persoons et al., 1995; Southwick et al., 1999; Yeh et al., 2002). Such down-regulation may contribute to the association between PTSD and decreased mtDNAcn. First, both increased and decreased glucocorticoid activity can be detrimental for mitochondria via multiple changes in mtDNA gene expression and increased reactive oxygen species (ROS) (Du et al., 2009; Picard et al., 2014a; Psarra and Sekeres, 2009, 2011; Tang et al., 2013). Second, in vitro studies (Garrett et al., 2014; Rasbach et al., 2010) show that agonists of 5-HT2 and 5-HT1F serotonin receptors may increase mtDNAcn in parallel with PGC-1α (peroxisome proliferator gamma coactivator 1α), a potent inducer of mitochondrial biogenesis (Fernandez-Marcos and Auwerx, 2011), suggesting a serotonergic-dependent mechanism controlling the expansion of mitochondrial content. Third, NO could act on mitochondria at several levels, and treatment of various cells with NO donors increases their mtDNA content (Kelly and Scarpulla, 2004; Nisoli and Carruba, 2006; Nisoli et al., 2003). Therefore, it is possible that down-regulated glucocorticoid, serotonergic or NO systems, which have been observed in some studies in PTSD (Bersani et al., 2015; Bugajski, 1999; Harris et al., 2000; Lopez-Figueroa et al., 1998; Meewisse et al., 2007; Persoons et al., 1995; Southwick et al., 1999; Yeh et al., 2002), may directly or indirectly contribute to reduced mtDNA replication or, although less likely, increased mtDNA degradation.

In addition, several PTSD-associated phenotypes (e.g. metabolic dysregulation, increased BMI, visceral adiposity, diabetes, insulin resistance (Levine et al., 2014)) are themselves associated with lowered mtDNAcn (Choi et al., 2001; Kim et al., 2012; Lee et al., 1998, 2014). However, we did not observe significant correlations between BMI and mtDNAcn in our samples.

At an organismal level, PTSD may be associated with aspects of accelerated biological aging (Bremner and Narayan, 1998; Miller and Sadeh, 2014; Moreno-Villanueva et al., 2013; Torgashov et al., 2013; Yehuda, 2005), and decreased mtDNAcn could be further evidence of this (Bratic and Larsson, 2013). One proposed index of accelerated biological aging in PTSD is premature telomere shortening (Jergovic et al., 2014; O’Donovan et al., 2011). Telomere length is genetically and epigenetically determined (Chan and Blackburn, 2004) and is also subject to shortening by cellular stresses such as oxidation and inflammation (Chan and Blackburn, 2004). Critically shortened telomeres elicit sustained DNA damage responses, such as activation of tumor suppressor protein p53 (Sahin et al., 2011), with outcomes that can include altered transcriptional program, cell cycle arrest, cellular senescence or apoptosis (Sahin et al., 2011). Activation of p53 can also decrease the expression of PGC-1α with subsequent decrease of mitochondrial function and mtDNAcn (Sahin et al., 2011).

Our second finding was an "inverted-U"-shaped relationship between PTSD symptom severity and mtDNAcn in the PTSD sample, although this was not hypothesized a priori and therefore requires replication. Specifically, we found that moderate levels of PTSD...
Symptom severity were associated with relatively higher mtDNAcn compared to both low and high levels of symptom severity. There are several models by which mtDNAcn could show an “inverted-U” relationship with symptom severity. One model has been termed “mitochondrial allostatic load,” in which conditions of mild cellular stress increase mitochondrial biogenesis and mtDNAcn, perhaps as a compensatory response, while higher or more chronic cellular stress leads to mitochondrial damage and dysfunction, perhaps due to exceeding compensatory capacity (Handschin and Spiegelman, 2006; Moyes et al., 1998; Picard et al., 2014a; Scarpulla et al., 2012; Yu-Wai-Man et al., 2010). Therefore, the relative increase of mtDNAcn from mild to moderate PTSD severity could be explained by a compensatory adaptive increase of mtDNA proliferation, which may be driven by (i) the activation of PGC-1α proteins (Handschin and Spiegelman, 2006; Moyes et al., 1998; Scarpulla et al., 2012), and (ii) the translocation of telomerase reverse transcriptase (TERT; the catalytic subunit of telomerase) from the nucleus to the mitochondria with subsequent mitochondrial protection (Jaiswal et al., 2013; Saretzki, 2009). On the other hand, the relative decrease of mtDNAcn from moderate to severe PTSD severity might be explained by evidence that, in the presence of high levels of cellular stressors, up to 80–90% of TERT shuttles to the mitochondria (Ahmed et al., 2008), leading to insufficient nuclear telomere protection with subsequent telomere shortening cellular and mitochondrial damage (described above) (Ahmed et al., 2008; Saretzki, 2009). These scenarios, however, remain purely hypothetical, but may be useful in guiding future research.

Our final major finding was the positive correlation of mtDNAcn with PANAS positive subscale ratings, but not with PANAS negative subscale, ETI or BD-II depression ratings. This, too, was not hypothesized a priori; therefore it is also considered preliminary and in need of replication. The finding is, however, consistent with preliminary evidence of a significant positive correlation between mtDNAcn and PANAS positive subscale in individuals with MDD (Lindqvist et al., 2015).

4.1. Strengths and limits

Limitations of the present study include our use of an all male study sample; future studies, including an ongoing one by our group, will be needed to investigate biological parameters in combat-exposed females with or without PTSD. Since this was a cross-sectional study based on single time-point blood and behavioral measurements, we cannot determine moment-to-moment variability in the measures, and we cannot assess causal mediation models. Also, our study measured mtDNAcn in granulocytes; therefore, these results cannot uncritically be extrapolated to other cell types or tissues. While a strength of our study is our use of a combat-exposed non-PTSD group, since the non-specific effects of combat exposure are controlled for, we recognize that individuals who did not develop PTSD despite combat exposure may represent especially resilient individuals rather than normative control subjects. Also, we did not have diagnostic data on subsyndromal depression or other anxiety disorders besides obsessive–compulsive disorder, and the possible impact of these variables is not known. Finally, we are not proposing mtDNAcn as a biomarker for PTSD, both because we do not have data regarding its specificity for PTSD, and because our subjects with moderate PTSD did not differ from controls in mtDNAcn.

Strengths of the present study are that the sample was clinically well-characterized, information on potential covariates was available (medical illness, BMI, comorbid depression, medication, cigarette usage, time since index trauma event, etc.), all blood samples were drawn fasting and at the same time of day, and all assays were conducted in the same lab. An additional strength of the present study is its sample of relatively young war veterans, since age-related illnesses can pose significant confounds in studies of psychiatric disorders in older subjects and in studies of mtDNA (Mengel-From et al., 2014).

4.2. Conclusion

The present study provides the first evidence that the granulocyte mtDNAcn is decreased in combat-exposed men with PTSD, has a possible “inverted-U” shaped relationship with PTSD symptom severity, and is positively associated with positive affectivity. These findings add to the accumulating evidence that mitochondrial dysfunction is associated with, and may underlie, some of the psychiatric, physical and biological manifestations of PTSD, and contribute to an expanded view of PTSD, as being—in addition to a mental illness—an illness with important somatic underpinnings. If these findings are replicated in studies with larger samples and longitudinal designs, assessment of mtDNAcn could help clarify aspects of the pathophysiology of PTSD and could point to novel markers and treatment targets.

Acknowledgments

This study was supported by the following grants: U.S. Department of Defense, W81XWH-11-2-0223 (Pt: Charles Marmar); U.S. Department of Defense, W81XWH-10–1-0021 (Pt: Owen M. Wolkowitz); and The Mental Illness Research, Education and Clinical Center (MIRECC). Daniel Lindqvist received financial support from the Sjobring Foundation; the OM Pearson Foundation and the Province of Scania (Sweden) state grants (ALF). The authors declare no conflict of interest. This publication arises from collaborative activities among eight institutions under the U.S. Department of Defense contract “Systems Biology Studies of PTSD”: University of California San Francisco, New York University, Icahn School of Medicine at Mt. Sinai, US Army Medical Command (MEDCOM), University of California Santa Barbara, Institute for Systems Biology, Emory University and the Veterans Administration Health Care System.

References


M. Yu, et al., 2010. OPA1 mutations cause cytochrome c oxidase deficiency due to loss of wild-type mtDNA molecules. *Hum. Mol. Genet.* 19, 3043–3052.